TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19032733

Group type: EXPERIMENTAL
Intervention: CRT selected based on echocardiographic parameters of myocardial asynchrony
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (historic CRT patients not screened for asynchrony)
Number of subjects: 16
Study: 17150108

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA), mean dose of 850 mg/d for 18 months (range 6-27 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Valproic acid (Control group)
Number of subjects: 40
Study: 14695410

Group type: EXPERIMENTAL
Intervention: 75 g of sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (660 ml beverage with artificial sweeteners)
Number of subjects: 12
Study: 10821079

Group type: EXPERIMENTAL
Intervention: Econazole nitrate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Econazole nitrate, Miconazole, Nystatin
Number of subjects: 75
Study: 8693170

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells Collection (PBSCC)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Bone Marrow Collection (BMC)
Number of subjects: 199
Study: 1796197

Group type: EXPERIMENTAL
Intervention: morniflumate combined with amoxicillin
Number of subjects: 60

Group type: COMPARATOR
Intervention: imidazole-2-hydroxybenzoate combined with amoxicillin
Number of subjects: 60

Group type: COMPARATOR
Intervention: antibiotic therapy alone
Number of subjects: 60
Study: 6666232

Group type: EXPERIMENTAL
Intervention: ISDN (3 mg intracoronary)
Number of subjects: 13

Group type: COMPARATOR
Intervention: ASA (1.0 g intravenous and 100 mg intracoronary)
Number of subjects: 13

Group type: COMPARATOR
Intervention: ASA (before ISDN administration)
Number of subjects: 13
Study: 30803137

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous chloride toothpaste
Number of subjects: 240

Group type: COMPARATOR
Intervention: Monofluorophosphate toothpaste
Number of subjects: 240
Study: 28866447

Group type: EXPERIMENTAL
Intervention: Verum tDCS (2-mA, twice-daily sessions for 5-days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sham-to-verum crossover in OLE phase
Number of subjects: 25
Study: 27228435

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029

Group type: EXPERIMENTAL
Intervention: Candesartan (within 6h of stroke onset)
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2029
Study: 24687165

Group type: EXPERIMENTAL
Intervention: Brachial-ankle PWV
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Femoral-ankle PWV
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Central stiffness (carotid-femoral PWV)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Central stiffness (heart-femoral PWV)
Number of subjects: 81
Study: 22563194

Group type: EXPERIMENTAL
Intervention: LCR35 (n = 25) at a minimum daily dose of 6 × 10(8) colony forming units for 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LCR35 in IBS patients with predominance of diarrhoea
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 25) for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo in IBS patients with predominance of constipation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo in IBS patients with unsubtyped IBS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LCR35 in mixed IBS patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo in mixed IBS patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: LCR35 and Placebo in both groups
Number of subjects: 50
Study: 20090320

Group type: EXPERIMENTAL
Intervention: Filter-protected CAS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unprotected CAS
Number of subjects: 30
Study: 17661765

Group type: EXPERIMENTAL
Intervention: Oral chili (5 g daily x 3 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral chili with 1-mg intravenous granisetron
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous granisetron after placebo ingestion
Number of subjects: 18
Study: 16310024

Group type: EXPERIMENTAL
Intervention: Psychological stressor (administered to 21 patients during the last 90 min of 24-h oesophageal pH monitoring)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No-stress control condition (administered to the remaining participants)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Participants with greater state anxiety
Number of subjects: 42
Study: 11903027

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 281

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stroke rate
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 281
Study: 10203878

Group type: EXPERIMENTAL
Intervention: 25% of the 4-hourly opioid dose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50% of the 4-hourly opioid dose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both regimens (25% and 50%)
Number of subjects: 33
Study: 7780069

Group type: COMPARATOR
Intervention: Meperidine, 25 to 75 mg (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vecuronium, 0.1 microgram/kg (n = 10), continued as an infusion at 1.0 microgram/kg/min for 4 hours
Number of subjects: 20
Study: 2109023

Group type: EXPERIMENTAL
Intervention: Serum levels of TNF
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum levels of IL-1 beta
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum levels of IFN alpha
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum levels of IFN gamma
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Severity of underlying disease
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Age of the patient
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Documentation of infection (nonbacteremic infections vs. bacteremias)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Urine output
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Arterial pH
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Median concentration of TNF in survivors after 10 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Median concentration of TNF in nonsurvivors after 10 days
Number of subjects: 70
Study: 393465

Group type: EXPERIMENTAL
Intervention: Protacine (150 mg, 3 times daily for 21 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Indomethacin (50 mg, 3 times daily for 21 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Protacine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 69
Study: 30649375

Group type: EXPERIMENTAL
Intervention: Micafungin 100mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Micafungin 200mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Micafungin 300mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loading dose (twice the maintenance dose)
Number of subjects: 24
Study: 28816867

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua and Proclear Multifocal Distance and Near (Group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua, Air Optix Multifocal, and PureVision Multifocal (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single vision control lens
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Center-distance lens
Number of subjects: 35
Study: 25557742

Group type: EXPERIMENTAL
Intervention: Type I collagen skin substitute
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard-of-care wound dressings
Number of subjects: 10
Study: 23456790

Group type: EXPERIMENTAL
Intervention: Ultrasound scan arm (TVS)
Number of subjects: 202638
Study: 22008746

Group type: EXPERIMENTAL
Intervention: PEG hydrogel spinal sealant
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 158
Study: 19208047

Group type: EXPERIMENTAL
Intervention: Electronic temperature device (1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Disposable temperature device
Number of subjects: 72
Study: 17083638

Group type: EXPERIMENTAL
Intervention: Method one (blood taken directly from cannula hub)
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Method two (blood taken using an Interlink device through cannula cap)
Number of subjects: 1390
Study: 14979213

Group type: EXPERIMENTAL
Intervention: Keyouling oral liquid (high-dosage group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Keyouling oral liquid (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11305831

Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (Group-CL, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam (Group-DZ, n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Group-P, n=20)
Number of subjects: 60
Study: 9220179

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 micrograms/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous bumetanide (1 mg b.i.d.) alone
Number of subjects: 20
Study: 11767421

Group type: EXPERIMENTAL
Intervention: Netilmicin 2 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cefuroxime 20 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metronidazole 7.5 mg kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cefuroxime 20 mg kg‐1 and Metronidazole 7.5 mg kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3329738

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal‐LA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 95
Study: 29570588

Group type: EXPERIMENTAL
Intervention: Early initiation of parenteral nutrition
Number of subjects: 37

Group type: COMPARATOR
Intervention: Late initiation of parenteral nutrition
Number of subjects: 37
Study: 25768376

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg for intubation followed by sugammadex 4.0 mg/kg for reversal.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg/kg for intubation with spontaneous recovery.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Succinylcholine group
Number of subjects: 150
Study: 24619151

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 978

Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 978
Study: 22672501

Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin
Number of subjects: 60

Group type: COMPARATOR
Intervention: metformin only
Number of subjects: 60
Study: 19897503

Group type: EXPERIMENTAL
Intervention: Paced RV-LV interlead electrical delay during RV and LV pacing
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: DeltapRV-LV interlead electrical delay
Number of subjects: 52

Group type: COMPARATOR
Intervention: RV-LV interlead electrical delay during spontaneous rhythm
Number of subjects: 52
Study: 18053311

Group type: EXPERIMENTAL
Intervention: Three meals per day (breakfast, lunch, dinner)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Two meals per day (breakfast, dinner)
Number of subjects: 14
Study: 17121765

Group type: EXPERIMENTAL
Intervention: Bromelain 800 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12933427

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.75 micro g/kg in bolus, followed by continuous infusion of 0.075 micro g x kg(‐1) x min(‐1) (Group L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 micro g/kg in bolus, followed by continuous infusion of 0.15 micro g x kg(‐1) x min(‐1) (Group H)
Number of subjects: 24
Study: 11529283

Group type: EXPERIMENTAL
Intervention: Formoterol (twice daily 24 microg by Turbuhaler)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salmeterol (twice daily 100 microg by Diskhaler)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9170488

Group type: EXPERIMENTAL
Intervention: Immediate oxytocin induction
Number of subjects: 7493

Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandins
Number of subjects: 7493

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 7493
Study: 8220396

Group type: EXPERIMENTAL
Intervention: Amino acid (protein) capsules
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lactose (placebo) capsules
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Amino acid and Lactose)
Number of subjects: 28
Study: 3327931

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 12.5 mg twice daily)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 31389672

Group type: EXPERIMENTAL
Intervention: 0.02% PCA lotion for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo lotion for 8 weeks
Number of subjects: 22
Study: 30606315

Group type: EXPERIMENTAL
Intervention: Universal isoniazid preventive therapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QuantiFERON®‐TB Gold In‐Tube (QGIT) directed IPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: TST-directed IPT
Number of subjects: 0
Study: 28486342

Group type: EXPERIMENTAL
Intervention: Incentive-based intervention (n=51)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No incentive (n=48)
Number of subjects: 99
Study: 25680623

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (irinotecan, oxaliplatin, tegafur-uracil with leucovorin and cetuximab)
Number of subjects: 48
Study: 24156558

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Self-Directed Intervention (SDI) (control)
Number of subjects: 54
Study: 20878265

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Barbiturates
Number of subjects: 24
Study: 18510819

Group type: COMPARATOR
Intervention: Taste-masked quinine sulphate pellets (600 mg single dose for adults; 10-12.5 mg/kg every 8 hours for 7 days for children)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Commercially available tablets (control for adults)
Number of subjects: 56
Study: 16918261

Group type: EXPERIMENTAL
Intervention: Epratuzumab (humanised anti-CD22 antibody)
Number of subjects: 0
Study: 12665979

Group type: EXPERIMENTAL
Intervention: Optimal velocity (V(opt): 116.6 rpm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 50% Optimal velocity (0.5 V(opt): 60.6 rpm)
Number of subjects: 13
Study: 10740436

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: Pivampicillin 700 mg orally twice daily
Number of subjects: 172
Study: 8922570

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (40 mg/kg/d in two divided doses for five days)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Penicillin V (30 mg/kg/d in three divided doses for ten days)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 227

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate and Penicillin V
Number of subjects: 227
Study: 29390048

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1-3) (IMA)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard induction therapy with cytarabine (100 mg/m2 continuously days 1-7) plus daunorubicin (45 mg/m2 days 3-5) (DA)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine plus mitoxantrone (IMA)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Standard induction therapy with cytarabine plus daunorubicin (DA)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Both IMA and DA
Number of subjects: 485
Study: 28453759

Group type: EXPERIMENTAL
Intervention: Leukapheresis treatment with CCL25 column
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 26222774

Group type: EXPERIMENTAL
Intervention: eGFR <60 ml/min/1.73 m2 and elevated OPG
Number of subjects: 1292

Group type: COMPARATOR
Intervention: eGFR ≥60 ml/min/1.73 m2 and low OPG
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: elevated OPG and stage III CKD
Number of subjects: 1292
Study: 23690357

Group type: EXPERIMENTAL
Intervention: High-viscosity Glass-ionomer Cement (GIC) group
Number of subjects: 2640

Group type: EXPERIMENTAL
Intervention: Fluoride Resin-based group (fluoride-RB)
Number of subjects: 2640

Group type: COMPARATOR
Intervention: No-fluoride Resin-based group (RB)
Number of subjects: 2640
Study: 21384187

Group type: EXPERIMENTAL
Intervention: Transvaginal-hybrid cholecystectomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-port cholecystectomy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Four-trocar laparoscopic cholecystectomy
Number of subjects: 51
Study: 18805677

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 31
Study: 16507398

Group type: EXPERIMENTAL
Intervention: exemestane 25 mg daily and celecoxib 400 mg twice-daily (Group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: exemestane 25 mg daily (Group B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg daily (Group C)
Number of subjects: 41
Study: 12090818

Group type: EXPERIMENTAL
Intervention: Desipramine (mean total daily dose, 3.4 mg/kg per day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 41
Study: 10613165

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and exercise
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation as analgesic and exercise
Number of subjects: 49

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 49
Study: 7565526

Group type: EXPERIMENTAL
Intervention: Taped music intervention
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Vibrotactile intervention
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Taped music condition
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control condition (no music)
Number of subjects: 4
Study: 1951147

Group type: EXPERIMENTAL
Intervention: Large meal (LM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Small meals (SM)
Number of subjects: 7
Study: 7129746

Group type: EXPERIMENTAL
Intervention: Experimental condition (obese-adolescent females)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control condition (normal weight adolescent females)
Number of subjects: 68
Study: 30632924

Group type: EXPERIMENTAL
Intervention: Audio-recorded clinical hypnosis intervention
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Music session
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (waiting in the room before biopsy)
Number of subjects: 170
Study: 29061621

Group type: EXPERIMENTAL
Intervention: Primary care-based model of care (MoC) for FH detection and management.
Number of subjects: 0
Study: 25392341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 4 µg/cc
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 8 µg/cc
Number of subjects: 90
Study: 24811963

Group type: EXPERIMENTAL
Intervention: Aganirsen eye drops (86 μg/day/eye) applied twice daily for 90 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aganirsen eye drops
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 23146777

Group type: EXPERIMENTAL
Intervention: Curcumin ingestion for 8 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 19151567

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR for postoperative 10 months (1,200 mg/body/day for five days followed by two days rest)
Number of subjects: 239
Study: 17874490

Group type: EXPERIMENTAL
Intervention: 0.004% Travoprost
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15278273

Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin-impregnated catheters
Number of subjects: 465

Group type: COMPARATOR
Intervention: Non-impregnated catheters
Number of subjects: 465
Study: 11222112

Group type: EXPERIMENTAL
Intervention: Power spectral analysis (alpha TF)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Phenylephrine method (BS(phen))
Number of subjects: 142
Study: 9603683

Group type: EXPERIMENTAL
Intervention: Supervised home‐based moderate‐intensity physical activity regimen for four months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical inactivity
Number of subjects: 0
Study: 7960409

Group type: EXPERIMENTAL
Intervention: NODS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isopto‐NaturaleR
Number of subjects: 30
Study: 2448145

Group type: EXPERIMENTAL
Intervention: Combination doxorubicin and mitomycin C (DM)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Combination cisplatin, vinblastine and bleomycin (PVB)
Number of subjects: 95
Study: 30943497

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg plus Propranolol 40 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29208690

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.45 mg/day), n=18
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (50 μg/day) with oral micronized progesterone (Prometrium 200 mg), n=23
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo pills and patch, n=26
Number of subjects: 67
Study: 25488344

Group type: EXPERIMENTAL
Intervention: DC group (double-coated probiotic formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NC group (non-coated probiotic formulation)
Number of subjects: 40
Study: 23141486

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (DSR)
Number of subjects: 17